Not especially likely, IMO; if EDP-494 had activity against HBV, ENTA probably would have said so by now and they might have included an HBV cohort in the phase-1 trial (https://clinicaltrials.gov/ct2/show/NCT02652377 ).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.